154 related articles for article (PubMed ID: 24494692)
21. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
22. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Geethakumari PR; Cookson MS; Kelly WK;
Oncology (Williston Park); 2016 Feb; 30(2):187-95, 199. PubMed ID: 26888794
[TBL] [Abstract][Full Text] [Related]
23. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Advanced Prostate Cancer.
Teo MY; Rathkopf DE; Kantoff P
Annu Rev Med; 2019 Jan; 70():479-499. PubMed ID: 30691365
[TBL] [Abstract][Full Text] [Related]
25. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
Bennett CL; Matchar D; McCrory D; McLeod DG; Crawford ED; Hillner BE
Cancer; 1996 May; 77(9):1854-61. PubMed ID: 8646685
[TBL] [Abstract][Full Text] [Related]
26. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
27. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Climent MÁ; León-Mateos L; González Del Alba A; Pérez-Valderrama B; Méndez-Vidal MJ; Mellado B; Arranz JÁ; Sánchez-Hernández A; Cassinello J; Olmos D; Carles J
Crit Rev Oncol Hematol; 2015 Nov; 96(2):308-18. PubMed ID: 26100652
[TBL] [Abstract][Full Text] [Related]
28. Castration-resistant prostate cancer: AUA Guideline.
Cookson MS; Roth BJ; Dahm P; Engstrom C; Freedland SJ; Hussain M; Lin DW; Lowrance WT; Murad MH; Oh WK; Penson DF; Kibel AS
J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
[TBL] [Abstract][Full Text] [Related]
29. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
Mukherji D; Omlin A; Pezaro C; Shamseddine A; de Bono J
Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
[TBL] [Abstract][Full Text] [Related]
30. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden.
Svensson J; Lissbrant IF; Gauffin O; Hjälm-Eriksson M; Kilany S; Fagerlund K; Stattin P
Scand J Urol; 2021 Feb; 55(1):1-8. PubMed ID: 33300403
[TBL] [Abstract][Full Text] [Related]
31. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Bastos DA; Dzik C; Rathkopf D; Scher HI
Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
[TBL] [Abstract][Full Text] [Related]
32. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Benidir T; Hersey K; Finelli A; Hamilton R; Joshua AM; Kulkarni G; Zlotta A; Fleshner N
Urol Oncol; 2018 May; 36(5):240.e13-240.e20. PubMed ID: 29454590
[TBL] [Abstract][Full Text] [Related]
33. Clinical phenotypes of castration-resistant prostate cancer.
Zhang T; Armstrong AJ
Clin Adv Hematol Oncol; 2013 Nov; 11(11):707-18. PubMed ID: 24896544
[TBL] [Abstract][Full Text] [Related]
34. Lessons from in-vivo models of castration-resistant prostate cancer.
Lin D; Gout PW; Wang Y
Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
[TBL] [Abstract][Full Text] [Related]
35. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer.
Ishibashi Y; Tobisawa Y; Hatakeyama S; Ohashi T; Tanaka M; Narita S; Koie T; Habuchi T; Nishimura S; Ohyama C; Yoneyama T
Prostate; 2014 Nov; 74(15):1521-9. PubMed ID: 25154914
[TBL] [Abstract][Full Text] [Related]
36. Emerging drugs for prostate cancer.
Chung PH; Gayed BA; Thoreson GR; Raj GV
Expert Opin Emerg Drugs; 2013 Dec; 18(4):533-50. PubMed ID: 24274615
[TBL] [Abstract][Full Text] [Related]
37. Castration-resistant prostate cancer: adaptive responses in the androgen axis.
Egan A; Dong Y; Zhang H; Qi Y; Balk SP; Sartor O
Cancer Treat Rev; 2014 Apr; 40(3):426-33. PubMed ID: 24139549
[TBL] [Abstract][Full Text] [Related]
38. The utility of prostate-specific antigen in the management of advanced prostate cancer.
Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
[TBL] [Abstract][Full Text] [Related]
39. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery.
Sciarra A; Cattarino S; Gentilucci A; Alfarone A; Innocenzi M; Gentile V; Salciccia S
Urol Oncol; 2013 Jul; 31(5):607-14. PubMed ID: 21665494
[TBL] [Abstract][Full Text] [Related]
40. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
